Home ADNKronos Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
 

Immediapress

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

 

(Adnkronos) - LONDON, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have approved Kanna Health's Investigational New Drug (IND) application and Clinical Tria

I contenuti di VeneziePost sono a pagamento.
Per visualizzare questo articolo e tutti i nostri contenuti scegli tra queste opzioni
Sei già iscritto a VeneziePost?
Clicca qui sotto e inserisci le tue credenziali
Accedi
Facebook Twitter Linkedin Email